NCT02701257 is a NA clinical trial of iPhone bionic pancreas in Diabetes Mellitus Type 1, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT02701257?

NCT02701257 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT02701257?

Interventions in NCT02701257: iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set.

What condition does NCT02701257 study?

NCT02701257 studies Diabetes Mellitus Type 1.

Is NCT02701257 still recruiting?

NCT02701257 is currently terminated. Last updated 15 November 2019.

Are results published for NCT02701257?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-11-15 · How we verify

NCT02701257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

Terminated NA Results posted Last updated 15 November 2019

What this trial tests

NA trial testing iPhone bionic pancreas in Diabetes Mellitus Type 1 in 20 participants. Terminated before completion.

Timeline

1 March 2016

Primary endpoint
1 May 2018

1 May 2018

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 March 2016
Primary completion	1 May 2018
Estimated completion	1 May 2018
Sites	1 location across United States

Drugs / interventions tested

iPhone bionic pancreas
iLet bionic pancreas
Xeris Xerisol glucagon — full drug profile →
Lilly glucagon — full drug profile →
iLet infusion set
Contact Detach infusion set

Conditions studied

Diabetes Mellitus Type 1 — all drugs for Diabetes Mellitus Type 1 →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Diabetes Mellitus Type 1. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Average Percent Dose Amounts Calculated by the Bionic Pancreas Control Algorithm That Are Successfully Delivered by the Pump (Aggregate of Both Insulin and Glucagon Doses)
Time frame: 8 hours
Average percent dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump (aggregate of both insulin and glucagon doses) - primary outcome for iPhone-based BP using Lilly glucagon vs. iLet BP using Lilly glucagon
Average Percent Dose Amounts Calculated by the Bionic Pancreas Control Algorithm That Are Successfully Delivered by the Pump (Glucagon Doses).
Time frame: 8 hours
Average percent dose amounts calculated by the bionic pancreas control algorithm that are successfully delivered by the pump (glucagon doses) - - primary outcome for iLet BP using Lilly glucagon vs. iLet BP using Xeris Xerisol glucagon
Insulin Area Under the Curve in the 3.5 Hours Following the Insulin Bolus
Time frame: 3.5 hours following insulin bolus
This applies only to the infusion set sub-study

Sponsor's own description

This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes. Both bionic pancreas devices measure glucose levels every five minutes and then give insulin and/or glucagon automatically to regulate the blood glucose (BG).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus Type 1

Currently open trials in the same condition.

NCT07091318 — CBTi for the Treatment of Insomnia in Type 1 Diabetes · EARLY_PHASE1 · recruiting
NCT07320495 — Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery · NA · recruiting
NCT06936280 — Type 1 Diabetes and Diabetes Distress · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02701257 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 15 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02701257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing